Compare Inovio Pharmaceuticals Inc (INO) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while YieldMax NVDA Option Income Strategy ETF trades at $12.58 (market cap $1.45B). The key difference: YieldMax NVDA Option Income Strategy ETF is far larger — about 12.9× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is more actively traded (3,201,278 versus 1,943,739). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and YieldMax NVDA Option Income Strategy ETF for 43 Days on average.
| INO | NVDY | |
|---|---|---|
Market Cap | $112.19M | $1.45B |
Volume | 3,201,278 | 1,943,739 |
Sector | Health | Income / Options Overlay |
52-Week High | $2.65 | $17.21 |
52-Week Low | $0.66 | $11.58 |
Typical Hold Time | 43 Days | 43 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
NVDY trades at $12.565, down 3.42% today amid bearish technical signals. The ETF shows consistent weekly dividend distributions but faces structural limitations on upside participation. Recent analyst coverage highlights declining volatility in underlying NVDA shares, reducing option income potential while NAV erosion remains a concern.
Outlook remains cautious as the fund's high distribution yield comes at the cost of long-term capital appreciation. Key risks include capped upside participation and dependency on NVDA volatility. Investors seeking pure NVDA exposure may find direct ownership more attractive for growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
